ERLANGER Home
HealthLink Plus For Vendors For the Media Physician Relations and Recruitment
975 East Third Street
Chattanooga, TN 37403
423-778-7000
Children's Hospital at Erlanger Erlanger Baroness Campus Erlanger Bledsoe Campus Erlanger East Campus Erlanger North Campus UT Erlanger Physicians Group





Online Prereg
Register for a Class or Event
New Foundations Page
Print   Email

Leukemia

 

 

Acute Myeloid Leukemia (AML)

 E2906                               Principal Investigator: Larry Schlabach, MD

                                                Co-Investigator: John McCravey, MD and Matt Graham, MD

Title: Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Inductionand Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥ 60 Years) (IRB#: N/A)

NCT #: NCT01041703        Phase: Phase III

Purpose:This randomized phase III trial is studying clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia.

Drugs possibly given:
Clofarabine
Cytarabine
Daunorubicin hydrochloride
Decitabine

 Please view complete information about this trial at: http://www.clinicaltrial.gov/ct2/show/NCT01041703?term=E2906&rank=1